Sensory-Motor Systems Lab, Institute of Robotics and Intelligent Systems, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland; Spinal Cord Injury Center, University Hospital Balgrist, University of Zurich, Zurich, Switzerland.
Zürcher Höhenkliniken, Wald, Switzerland.
Lancet Neurol. 2014 Feb;13(2):159-66. doi: 10.1016/S1474-4422(13)70305-3. Epub 2013 Dec 30.
Arm hemiparesis secondary to stroke is common and disabling. We aimed to assess whether robotic training of an affected arm with ARMin--an exoskeleton robot that allows task-specific training in three dimensions-reduces motor impairment more effectively than does conventional therapy.
In a prospective, multicentre, parallel-group randomised trial, we enrolled patients who had had motor impairment for more than 6 months and moderate-to-severe arm paresis after a cerebrovascular accident who met our eligibility criteria from four centres in Switzerland. Eligible patients were randomly assigned (1:1) to receive robotic or conventional therapy using a centre-stratified randomisation procedure. For both groups, therapy was given for at least 45 min three times a week for 8 weeks (total 24 sessions). The primary outcome was change in score on the arm (upper extremity) section of the Fugl-Meyer assessment (FMA-UE). Assessors tested patients immediately before therapy, after 4 weeks of therapy, at the end of therapy, and 16 weeks and 34 weeks after start of therapy. Assessors were masked to treatment allocation, but patients, therapists, and data analysts were unmasked. Analyses were by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT00719433.
Between May 4, 2009, and Sept 3, 2012, 143 individuals were tested for eligibility, of whom 77 were eligible and agreed to participate. 38 patients assigned to robotic therapy and 35 assigned to conventional therapy were included in analyses. Patients assigned to robotic therapy had significantly greater improvements in motor function in the affected arm over the course of the study as measured by FMA-UE than did those assigned to conventional therapy (F=4.1, p=0.041; mean difference in score 0.78 points, 95% CI 0.03-1.53). No serious adverse events related to the study occurred.
Neurorehabilitation therapy including task-oriented training with an exoskeleton robot can enhance improvement of motor function in a chronically impaired paretic arm after stroke more effectively than conventional therapy. However, the absolute difference between effects of robotic and conventional therapy in our study was small and of weak significance, which leaves the clinical relevance in question.
Swiss National Science Foundation and Bangerter-Rhyner Stiftung.
中风导致的手臂偏瘫很常见且具有致残性。我们旨在评估,在经过 6 个月以上的病程,且因中风导致上肢运动功能中度至重度受损的患者中,使用 ARMin 机器人(一种可在三维空间中进行任务特定训练的外骨骼机器人)进行手臂训练是否比传统疗法更有效地降低运动功能障碍。
在一项前瞻性、多中心、平行组随机试验中,我们从瑞士的 4 个中心招募了符合纳入标准的患者。这些患者在中风后 6 个月以上且上肢运动功能仍存在中度至重度瘫痪,且上肢运动功能评估(FMA-UE)的手臂(上肢)部分评分>15 分。符合条件的患者以 1:1 的比例随机分配(采用中心分层随机分组程序)接受机器人或传统疗法。对于两组患者,每周治疗 3 次,每次至少 45 分钟,共 8 周(共 24 次)。主要结局是 Fugl-Meyer 评估(FMA-UE)手臂部分评分的变化。评估者在治疗前、治疗 4 周后、治疗结束时以及治疗开始后 16 周和 34 周时对患者进行测试。评估者对治疗分配设盲,但患者、治疗师和数据分析师均不设盲。分析采用改良意向治疗。本研究在 ClinicalTrials.gov 注册,编号为 NCT00719433。
2009 年 5 月 4 日至 2012 年 9 月 3 日,共有 143 人接受了入选标准的检测,其中 77 人符合条件并同意参加。38 名接受机器人治疗的患者和 35 名接受传统治疗的患者纳入分析。与接受传统治疗的患者相比,接受机器人治疗的患者在研究过程中手臂运动功能的改善明显更大,用 FMA-UE 评估为 0.78 分(F=4.1,p=0.041;95%CI 0.03-1.53)。没有与研究相关的严重不良事件发生。
神经康复治疗包括使用外骨骼机器人进行任务导向训练,可以比传统疗法更有效地提高中风后慢性受损瘫痪上肢的运动功能。然而,我们研究中机器人治疗和传统治疗的效果之间的绝对差异较小,且具有统计学意义,这使得其临床相关性受到质疑。
瑞士国家科学基金会和 Bangerter-Rhyner 基金会。